Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which one in four middle-aged adults in development countries expected to develop AF.1
By 2030, 14-17 million AF patients are anticipated in the European Union, with 120,000-215,000 newly diagnosed patients per year. Atrial fibrillation is associated with an increased risk of death and high levels of morbidity, such as heart failure and stroke.2
This means increased mortality, especially cardiovascular mortality due to sudden death, heart failure or stroke. 20-30% of all strokes are caused by Atrial fibrillation. Frequent and prolonged hospital stays are the consequences of a reduced quality of life.
A growing number of patients with stroke are diagnosed with ‘quiet’ atrial fibrillation.3
The aim of effective treatment of atrial fibrillation is to normalise the heart rate and prevent the resulting negative effects on the organism. Landiolol, currently the most effective highly selective beta blocker, significantly contributes to the advances in treatment of atrial fibrillation.
1, 2, 3: ESC Pocket Guidelines, European Society of Cardiology, Deutsche Gesellschaft für Kardiologie, Version 2016, Management von Vorhofflimmern, Empidemiologie und Auswirkung auf den Patienten, page 5